173 related articles for article (PubMed ID: 12063677)
21. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
King TC; Estalilla OC; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
[TBL] [Abstract][Full Text] [Related]
22. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
23. Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.
Prescott JL; Montie J; Pugh TW; McHugh T; Veltri RW
Cancer; 2001 Jun; 91(11):2127-35. PubMed ID: 11391594
[TBL] [Abstract][Full Text] [Related]
24. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
25. Computer program for the analysis of mutational spectra: application to p53 mutations.
Cariello NF; Piegorsch WW; Adams WT; Skopek TR
Carcinogenesis; 1994 Oct; 15(10):2281-5. PubMed ID: 7955067
[TBL] [Abstract][Full Text] [Related]
26. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations?
Pfeifer GP; Denissenko MF
Environ Mol Mutagen; 1998; 31(3):197-205. PubMed ID: 9585258
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
28. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
[TBL] [Abstract][Full Text] [Related]
29. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
30. Mutation and altered expression of p53 genes in experimental rat bladder tumor cells.
Jones RF; Matuszyk J; Debiec-Rychter M; Wang CY
Mol Carcinog; 1994 Feb; 9(2):95-104. PubMed ID: 8142014
[TBL] [Abstract][Full Text] [Related]
31. The p53 tumor suppressor gene: from molecular biology to clinical investigation.
Soussi T
Ann N Y Acad Sci; 2000 Jun; 910():121-37; discussion 137-9. PubMed ID: 10911910
[TBL] [Abstract][Full Text] [Related]
32. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
33. p53 gene mutations are not required for early dissemination of cancer cells.
Offner S; Schmaus W; Witter K; Baretton GB; Schlimok G; Passlick B; Riethmüller G; Pantel K
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6942-6. PubMed ID: 10359818
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
35. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
[TBL] [Abstract][Full Text] [Related]
36. Tumor-suppressor p53: implications for tumor development and prognosis.
Kirsch DG; Kastan MB
J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588
[TBL] [Abstract][Full Text] [Related]
37. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
Dahse R; Gärtner D; Werner W; Schubert J; Junker K
Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
[TBL] [Abstract][Full Text] [Related]
38. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers.
Chang YL; Wu CT; Lin SC; Hsiao CF; Jou YS; Lee YC
Clin Cancer Res; 2007 Jan; 13(1):52-8. PubMed ID: 17200338
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of p53 mutations in lung cancer.
Campling BG; el-Deiry WS
Methods Mol Med; 2003; 75():53-77. PubMed ID: 12407735
[TBL] [Abstract][Full Text] [Related]
40. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
